

Substitute for Form 1449 A &amp; B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

1

of

1

Complete if Known

Application Number	Based on PCT/JP04/016056
Confirmation Number	Unknown
Filing Date	October 22, 2004
First Named Inventor	Kazuyuki OHMOTO
Art Unit	Unknown
Examiner Name	Unknown
Attorney Docket Number	Q94625

## U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number	Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		US			

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Translation <sup>6</sup>
		Country Code <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)			
		WO	98/14213	A	04-09-1998	Daiichi Pharmaceutical Co., Ltd.	
		WO	03/68753	A1	08-21-2003	Ono Pharmaceutical Co., Ltd.	
		JP	2001-199982	A	07-24-2001	Dainippon Pharmaceutical Co., Ltd.	
		WO	03/82191	A	10-09-2003	MERCK & CO., INC.	
		WO	02/20495	A	03-14-2002	CHIRON CORP.	
		WO	02/92573	A2	11-21-2002	VERTEX PHARMACEUTICALS INC.	
		JP	2003-523380	A	08-05-2003	F. Hoffman-La Roche AG	
		JP	2002-510322	A	04-02-2002	Du Pont Pharmaceuticals Co.	
		WO	02/79197	A	10-10-2002	VERTEX PHARMACEUTICALS INC.	
		WO	03/35639	A1	03-01-2003	Eisai Co., Ltd.	
		WO	02/96421	A1	12/05/2002	NEUROGEN CORP.	
		JP	10-226649	A	08-25-1998	Tanabe Seiyaku Co., Ltd.	
		WO	00/73279	A	12-07-2000	F. Hoffman-La Roche AG	
		JP	2001-525794	A	12-11-2001	F. Hoffman-La Roche AG	
		WO	03/72107	A1	09-04-2003	PHARMACIA & UPJOHN CO.	
		WO	03/45924	A1	06-05-2003	PHARMACIA & UPJOHN CO.	
		JP	11-209350	A	08-03-1999	Eisai Co., Ltd.	
		WO	96/32384	A1	10-17-1996	Taiho Pharmaceutical Co. Ltd.	
		WO	03/29248	A1	04-10-2003	CYCLACEL LIMITED	
		JP	3-7266	A	01-14-1991	Shiratori Pharmaceutical Co., Ltd.	
		JP	6-501926	A	03-03-199	Fujisawa Pharmaceutical Co., Ltd.	
		WO	02/49648	A1	06-27-2002	SCHERING CORP.	
		WO	03/62871	A	08-07-2003	NOVARTIS PHARMA GMBH	

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	Translation <sup>6</sup>
		KATSUNAO TANAKA, et al., "Synthesis of a Magnosalin Derivative, 4-(3,4,5-trimethoxyphenyl)-6-(2,4,5-trimethoxyphenyl)-2-diethylaminopyrimidine, and the Anti-Angiogenic and Anti-Rheumatic Effect of Mice by Oral Administration", Bioorganic & Medicinal Chemistry Letters 12, 2002, pp. 623-627, Vol. 12, No. 4	
		International Search Report for PCT/JP04/016056 dated December 14, 2004	

Examiner Signature

/Deepak Rao/

Date Considered

08/31/2009

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /DR/

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kind Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04 or follow the hyperlink from the title of the document to the intranet. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to indicate here if English language Translation is attached.